NIST Workshop: Launch of the Rapid Microbial Testing Methods Consortium

Thursday, September 17, 2020, 1 PM to 5 PM

AGENDA

INTRODUCTORY REMARKS		
1:00 PM – 1:10 PM	Welcome and Overview RMTM Consortium and Workshop Goals	
	NANCY LIN, Leader of the Biomaterials Group, Biosystems and Biomaterials Division (BBD), Material Measurement Laboratory (MML), NIST	
1:10 PM – 1:20 PM	Overview of NIST Advanced Therapy Program	
	SHENG LIN-GIBSON, Chief of the BBD, MML, NIST	
1:20 PM – 1:30 PM	Overview of NIST Microbial Metrology Program	
	SCOTT JACKSON, Leader of the Complex Microbial Systems Group, BBD, MML, NIST	

SESSION 1: CHALLENGES IN SELECTING AND APPLYING A RAPID MICROBIAL TEST Moderator: Jason Kralj, NIST		
1:30 PM – 2:00 PM	Key Characteristics of Rapid Microbial Test Methods for Cell and Gene Therapies SPENCER HOOVER, Independent Consultant	
2:00 PM – 2:20 PM	FDA Requirements and Recommendations for Sterility Testing of Regenerative Medicine Therapies JUDITH ARCIDIACONO, International Regulatory Expert, Standards	
2:20 PM – 3:05 PM	Liaison, FDA PANEL DISCUSSION: Measurement Challenges and Needs Moderator: Scott Jackson, NIST • SPENCER HOOVER, Independent Consultant • TOM LEACH, Associate Director, Drug Product Process Engineering and Packaging, AstraZeneca • CLAUDIA ZYLBERBERG, CEO, Akron Biotech	

3:05	PM –	3:15 PM	BREAK
0.00		0.10.10.	

SESSION 2: ONGOING AND NEW EFFORTS TO ADDRESS CHALLENGES Moderator: Sandra Da Silva, NIST		
3:15 PM – 3:20 PM	Introduction to Session 2 NANCY LIN, NIST	
3:20 PM – 3:35 PM	Progress Toward Documentary Standards to Support Rapid Microbial Testing DAWN HENKE, Senior Scientific Program Manager, Standards	
3:35 PM – 3:55 PM	Coordinating Body Rapid Detection of Bacteria and Fungi in ATMPs Prior Treatment – Validation of a Real-time PCR-based Test	
	KAI NESEMANN, Product Manager, Microbiology, Sartorius Lab Instruments GmbH & Co. KG	
3:55 PM – 4:45 PM	PANEL DISCUSSION: Potential Solutions and Paths for the Consortium	
	Moderator: Nancy Lin, NIST	
	 JUDITH ARCIDIACONO, International Regulatory Expert, Standards Liaison, FDA 	
	 RICHARD HAMMOND, Technology Director, Cambridge Consultants LTD 	
	 RICHARD MCFARLAND, Chief Regulatory Officer, ARMI BioFabUSA 	
	 STACY SPRINGS, Senior Director of Programs; Executive Director Biomanufacturing Initiatives, Massachusetts Institute of Technology's Center for Biomedical Innovation 	
	 RADHAKRISHNA TIRUMALAI, Principal Scientific Liaison, US Pharmacopeial Convention (USP) 	

CONCLUDING REMARKS	
4:45 PM – 5:00 PM	Summary and Next Steps
	NANCY LIN and SCOTT JACKSON, NIST